Roth Capital Issues Positive Estimate for BRTX Earnings

Biorestorative Therapies, Inc. (NASDAQ:BRTX) – Equities research analysts at Roth Capital raised their Q3 2025 earnings per share (EPS) estimates for shares of Biorestorative Therapies in a note issued to investors on Tuesday, August 12th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($0.38) for the quarter, up from their previous forecast of ($0.43). The consensus estimate for Biorestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for Biorestorative Therapies’ Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.47) EPS, FY2026 earnings at ($1.22) EPS and FY2027 earnings at $2.43 EPS.

Biorestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.11. Biorestorative Therapies had a negative return on equity of 137.00% and a negative net margin of 1,772.40%. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.34 million.

Biorestorative Therapies Price Performance

Shares of Biorestorative Therapies stock opened at $1.52 on Friday. Biorestorative Therapies has a one year low of $1.21 and a one year high of $2.55. The firm has a market capitalization of $12.13 million, a price-to-earnings ratio of -1.20 and a beta of 76.70. The business has a 50-day simple moving average of $1.60 and a 200 day simple moving average of $1.75.

Biorestorative Therapies announced that its Board of Directors has initiated a stock buyback plan on Tuesday, June 17th that permits the company to repurchase $2.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 15.9% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Hedge Funds Weigh In On Biorestorative Therapies

A hedge fund recently bought a new stake in Biorestorative Therapies stock. Citadel Advisors LLC bought a new position in Biorestorative Therapies, Inc. (NASDAQ:BRTX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned about 0.31% of Biorestorative Therapies as of its most recent SEC filing. 69.38% of the stock is currently owned by institutional investors.

Biorestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.